Our Stocks to Watch today include QuoteMedia, Inc. (OTCBB: QMCI), IMAX Corporation (NASD: IMAX), Edgeline Holdings, Inc. (OTCBB:ELHI), MM2 Group, Inc. (OTCBB: MMGP), Catalyst Pharmaceutical Partners, Inc. (NASD: CPRX)
Visit http://www.otcpicks.com/ to register for our Daily Market Mover’s Digest Newsletter, and Email Stock Watch Alerts
QUOTEMEDIA INC. (OTCBB: QMCI)
Detailed Quote: http://www.otcpicks.com/quotes/QMCI.php
Company Profile: http://www.otcpicks.com/quotemedia/quotemedia.htm
QuoteMedia, Inc. is a leading software developer and provider of real-time streaming financial market information, decision-support, news and research solutions to brokerage, financial services companies, business and media corporations. Among its many leading-edge products lines, the Company offers data feeds, news, dynamic market content solutions, interactive stock research tools, financial applications and real-time wireless applications. QuoteMedia provides data and services for companies such as the NASDAQ, the OTCBB, Dow Jones & Company, Forbes.com, Scotia Capital, Business Wire, Southwest Securities, Regal Securities, FBR Direct, Broadridge Financial Solutions, Inc., AIM Trimark, Zacks Investment Research, ChoiceTrade, QTrade, Schaeffer's Investment Research, Automated Financial Systems, WallStreet*E, and others. For more information, please visit: www.quotemedia.com.
QMCI News:
December 5 - QuoteMedia Brings Respected Market Data Industry Veteran Onboard; Opens NYC Office
QuoteMedia, Inc. (OTCBB: QMCI), a leading provider of market data, corporate research information and financial applications, announced today the appointment of Mr. George Katsch as Corporate Sales Director, to lead the company’s new office in New York City.
Mr. Katsch brings more than 15 years of experience in selling and supporting financial information and technology solutions to the Brokerage, Financial Service, Media Publishing and Investor Relations industries. Most recently, Mr. Katsch served as Vice President of Sales for FinancialContent, Inc., where he was responsible for business development and sales for the entire North American market. Mr. Katsch has also held key management positions with Standard and Poor’s and Interactive Data Corporation (Comstock), where he managed senior account representatives and support staff. He was principally responsible for maintaining over $50 million in revenues and generating new sales.
“George is very well-known as a successful, skilled professional in our industry, and we’re excited that he is joining the QuoteMedia sales team, heading up our New York office,” said Dave Shworan, CEO of QuoteMedia Ltd. “He brings a wealth of experience to our company, and skill sets that make him an immediately great fit with QuoteMedia, as we continue our explosive growth.”
“From within the industry, I’ve watched QuoteMedia’s remarkable growth over the past few years. I have been very impressed with QuoteMedia’s emergence as a major player in the financial data industry, and the potential for further growth is extraordinary,” said Mr. Katsch. “QuoteMedia is definitely going places, and I’m excited to be a part of it.”
IMAX CORPORATION (NASD: IMAX)
"Up 56.90% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/IMAX.php
IMAX Corporation, through its wholly owned subsidiaries, operates as an entertainment technology company. It specializes in digital and film-based motion picture technologies and large-format two-dimensional (2D) and three-dimensional (3D) film presentations. The company primarily engages in the design, manufacture, sale, and lease of theater systems based on patented technology for large-format, 15-perforation film frame, 70mm format theaters, including commercial theaters, museums and science centers, and destination entertainment sites. Its theater systems include projector, sound systems, and screens. IMAX Corporation also designs and manufactures high-end sound systems, as well as produces and distributes films for IMAX theaters. In addition, the company engages in the production, digital re-mastering, post-production, and distribution of 15/70-format films; the operation of IMAX theaters; and the provision of services in support of IMAX theaters and the IMAX theater network. Its institutional customers include science and natural history museums, zoos, aquaria, and other educational and cultural centers. The company also sells or leases its theater systems to theme parks, tourist destination sites, fairs, and expositions. It operates primarily in the United States, Canada, Mexico, Europe, and Asia. As of March 31, 2007, IMAX Corporation operated 284 IMAX theaters in 40 countries. The company was founded in 1967 and is headquartered in Mississauga, Canada.
IMAX News:
December 7 - IMAX signs 100-theatre deal with AMC EntertainmentTM
IMAX Corporation (NASD: IMAX) (TSX: IMX) and AMC Entertainment Inc. (AMC), one of the world's largest and most innovative theatrical exhibition companies, announced a joint-venture agreement to install 100 IMAX® digital projection systems at AMC locations in 33 major U.S. markets. The theatres will feature IMAX's digital projection system which is being developed for the IMAX MPX® theatre design. The agreement is projected to double IMAX's current commercial theatre footprint in North America and accelerates the momentum behind IMAX and AMC's transition to digital projection technology.
"We are committed to delivering a premium entertainment experience by offering a menu of entertainment alternatives inside our facilities," said Peter C. Brown, chairman and chief executive officer, AMC Entertainment Inc. "Our expanded relationship with IMAX and the deployment of its state-of-the-art, next-generation digital projection systems is a key part of our strategy of continuing to broaden and enhance the AMC experience. It also builds on the successful partnership we have had with IMAX since June of 2005 and complements our overall digital plan."
The rollout of the first 50 IMAX digital projection systems will begin in July 2008 at premier AMC theatre locations in 24 of the 33 selected markets, with an additional 25 scheduled for rollout in 2009 and 25 more in 2010. The IMAX theatres are slated to be installed in many of AMC's top-performing locations in the United States, including: AMC South Barrington 30, Chicago; AMC Mesquite 30, Dallas; AMC Gulf Pointe 30, Houston; AMC Century City 15, Los Angeles; AMC Empire 25, New York; AMC Neshaminy 24, Philadelphia; AMC Eastridge 15, San Francisco; AMC Hoffman Center 22, Washington D.C.
"The agreement cements a partnership between two great brands. Partnering with AMC in a theatre deal of this size and scope is a transformational moment for our company from both a financial and strategic perspective," said IMAX Co-Chairmen and Co-CEOs Richard L. Gelfond and Bradley J. Wechsler. "We couldn't be more pleased that The IMAX Experience® will be more accessible to consumers in nearly every major market in the United States. AMC is unique in the number of successful, stadium-seat megaplexes in locations that could accommodate this large number of new IMAX® theatres. Further, AMC's confidence in our digital projection system is a terrific endorsement. We look forward to rolling out our ground-breaking new technology and delivering the premium experience that moviegoers have come to expect from the IMAX® brand."
In October of this year, IMAX announced that it had moved up the launch date of its digital projection system to mid-2008 from its previously announced anticipated timeframe of the end of 2008 to mid-2009. The highly anticipated IMAX digital projection system will further enhance The IMAX Experience and help to drive profitability for studios, exhibitors and IMAX theatres by virtually eliminating the need for film prints, increasing program flexibility and ultimately increasing the number of movies shown on IMAX screens.
IMAX has already secured important parts of its film slate for 2008, 2009 and 2010 through agreements with major Hollywood studios including: The Spiderwick Chronicles (February 2008), Shine A Light (April 2008), Kung Fu Panda (June 2008), The Dark Knight (July 2008), Deep Sea-quel 3D (working title, February 2009), Monsters vs. Aliens 3D (March 2009), How to Train Your Dragon 3D (November 2009), Hubble 3D (working title, February 2010) and Shrek Goes Forth 3D (May 2010).
Added Messrs. Gelfond and Wechsler, "An agreement of this magnitude significantly jumpstarts our joint venture initiative, which we expect will generate increased recurring revenues for IMAX going forward. AMC's decision to enter into this agreement will accelerate the growth of our theatre network in North America and should help power the digital transition underway at our company, which we believe will help drive our operating and financial performance for years to come."
About AMC Entertainment Inc.
Headquartered in Kansas City, Mo., AMC Entertainment Inc. is one of the world's largest and most innovative theatrical exhibition companies. With a history of industry leadership dating back to 1920, the company today serves more than 230 million guests annually through interests in 358 theatres with 5,128 screens in six countries. Visit www.amctheatres.com for more information.
EDGELINE HOLDINGS (OTCBB: ELHI)
"Up 34.88% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/ELHI.php
Headquartered in Houston, Texas, Edgeline Holdings, Inc. is a publicly traded holding company that specializes in the area of discovering and acquiring leading-edge niche technologies. These technologies will be incubated and nurtured into market ready applications. Edgeline's current and prospective portfolio consists of early stage companies that require management expertise to further develop the technology to ultimately maximize the value of such technologies by bringing them to market through licensing arrangements and partnerships.
ELHI News:
December 5 - Edgeline Holdings Signs Exclusive Option Agreement with The University of Texas M. D. Anderson Cancer Center
Edgeline Holdings, Inc. (OTCBB:ELHI) announced today that it has signed an Option agreement with The University of Texas M. D. Anderson Cancer Center that provides Edgeline Holdings the exclusive right to negotiate a license to five technologies relating to the treatment of various cancers over a nine month period. During this period the company has the right to evaluate the patents rights, potential products and markets, and to negotiate a license for the use of these patents.
“This agreement gives us the necessary time to allow our subsidiary, Intertech Bio, to properly evaluate the potential of these technologies,” stated Leonard Ivins, Chief Executive Officer of Edgeline Holdings. “M. D. Anderson has been a leader in developing new cancer therapies and we are excited about the opportunity to work with such a great institution.”
MM2 GROUP, INC (OTCBB: MMGP)
"Up 13.33% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/MMGP.php
MM2 Group, Inc., through its subsidiary, Genotec Nutritionals, Inc., engages in the formulation, marketing, and distribution of nutritional supplements and vitamins in the United States. It sells various products, including fish oil, grape powder, resveratrol, lutein, and psyllium powder, as well as various custom formulations, such as formulations for diet, cardiac support, eye support, immunity support, and aging support. The company also sells custom formulations for pet care, including a shedding formula, a coat formula, dog and cat joint formulas, and pet multi-vitamins for dogs and cats. MM2 Group is based in Livingston, New Jersey.
MMGP News:
December 7 - MM2 Group Establishes New Venture for Sofgel Manufacture in China
MM2 Group, Inc. (OTCBB: MMGP) announced that its wholly-owned subsidiary, Genotec Nutritionals, Inc., a New York based nutraceutical company which generates its sales from the distribution of its branded products and through custom formulations for several large strategic partners, has entered into a strategic venture to manufacture sofgel capsules in Zhongsan City, China.
The current capacity of the state of the art plant is 1.5 billion capsules per year. The plant was designed and built according to the latest cGMP requirements, in full compliance with both U.S. and China standards. The plant is capable of expanding capacity to 5 billion sofgel capsules per year.
Genotec's partner in this new venture is Anshi Pharmaceutical (Zhongsan) Inc. of China.
Anshi Pharmaceutical is a well regarded company in China. Its Executive Chairman, Mr. Xiaoxian Xu, is a famous entrepreneur in China who previously founded Livzon Pharmaceutical Group, a well known publicly-traded pharmaceutical company in China. Anshi is well positioned to provide research and development, manufacturing, and export services to the pharmaceutical and nutraceutical industries in the United States.
George Kontonotas, President of Genotec, stated, "We are very excited about this venture. The plant is a China SFDA certified facility that complies with cGMP manufacturing standards. These high standards, which allow the plant to currently manufacture pharmaceuticals, make this among the highest quality plants which can be found manufacturing products in the nutritional supplement marketplace."
Mark Meller, CEO of MM2 Group, commented, "We have already met with some of the largest users of sofgels in the nutritional supplement market. Our current focus is to supply large quantities of Vitamin E capsules to several users. We are now negotiating supply agreements with various companies, and hope to be in a position to make several exciting announcements in the near future regarding sales activity from this new venture."
Meller continued, "We are excited about our business prospects. We recently announced net income of $951,855 for our fiscal first quarter, up from a loss of $1,379,761 in the same period last year. We announced last week that we secured a large $1.1 million order for our omega-3 fish oil sofgels. We also recently announced a listing on the Frankfurt Stock Exchange, which we expect will give us greater visibility in Europe and will provide us with an opportunity to broaden our shareholder base to Europe. We anticipate that we will be in a position to announce more exciting business developments in the near future."
CATALYST PHARMACEUTICALS PARTNERS (NASD: CPRX)
"Up 14.13% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/CPRX.php
Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for nine patents and four patents pending in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending in more than 30 countries. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs. CPP-109 recently was selected as one of the five most promising drugs entering Phase II trials in the July-September 2007 issue of The Ones To Watch, published by Thomson Scientific, a Thomson Corporation publication. For more information about the Company, go to www.catalystpharma.com.
CPRX News:
December 7 - Catalyst Pharmaceutical Partners Announces Positive Phase II Trial Results for Vigabatrin in the Treatment of Cocaine Addiction
Study Demonstrates Statistically Significant Efficacy vs. Placebo
Trial Conducted Under Direction of New York University School of Medicine
Catalyst Pharmaceutical Partners, Inc. (NASD: CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, announced positive initial top-line results from an investigator-initiated Phase II double-blind, placebo-controlled trial, which demonstrates that vigabatrin is effective for the treatment of cocaine addiction. Catalyst's lead compound, CPP-109, is bioequivalent to vigabatrin.
This 103 subject trial is the first randomized, double-blind, placebo- controlled clinical trial studying vigabatrin's effectiveness in treating cocaine addiction. These data show that a statistically significantly greater number of subjects treated with vigabatrin were able to abstain from cocaine usage during the last three weeks of the dosing period compared to those receiving placebo. Achievement of abstinence for an extended period during treatment is the critical first step for cocaine addicted patients to potentially achieve abstinence for much longer time periods. The data confirm the positive results seen in two previous open-label trials conducted in 2003 and 2004 by the same investigators.
Commenting on the trial results, Patrick J. McEnany, Catalyst's Chairman and Chief Executive Officer, stated, "This trial represents a key development in the field of cocaine addiction research. CPP-109, our product candidate based on vigabatrin, could have a significant impact on how patients struggling with cocaine addiction will be treated in the future. We believe that the success of the trial provides scientific proof of concept. We are highly encouraged by the top-line results and look forward to publication of the results in a peer-reviewed journal. Catalyst will also evaluate the methodology and results for their potential applicability to our ongoing U.S. Phase II trial evaluating CPP-109 for the treatment of cocaine addiction and to our planned U.S. Phase II trial evaluating CPP-109 for the treatment of methamphetamine addiction."
About The Trial
This trial is the third in a series of human trials conducted in Mexico, which successfully tested the safety and efficacy of vigabatrin to treat cocaine and/or methamphetamine addiction. These trials followed more than 15 years of animal studies conducted by Dr. Stephen Dewey at Brookhaven National Laboratory. All three human trials were conducted under the direction of Dr. Jonathan Brodie, the Marvin Stern Professor of Psychiatry at the New York University (NYU) School of Medicine and Dr. Emilia Figueroa, Director of the Clinica Integral de Tratamiento Contra las Adicciones, S.A. de C.V. The first two trials were small open-label studies. The trial's protocol was approved by NYU's Institutional Review Board in May 2006 and the Federal Commission for Sanitary Risks Protection (Mexico) in September 2006 and is registered at www.clinicaltrials.gov with the identifier NCT00527683. Catalyst provided financial support through an unrestricted gift to NYU.
One hundred and three community-based, non-hospitalized cocaine addicted individuals participated in this investigator-initiated, randomized, double- blind, placebo-controlled trial conducted at a single site in Mexico City. All subjects had ready access to cocaine and were self-motivated to stop their use. The trial was designed to show whether vigabatrin treatment could significantly increase abstinence compared to placebo. Subjects were randomly assigned to either a placebo or vigabatrin and were treated for a period of nine weeks. Of the 103 participants in the trial, 50 were treated with vigabatrin and 53 received placebo. Twice-weekly urine screening tests were obtained from each subject in order to objectively evaluate each subjects' cocaine use. All subjects were also offered one group counseling session per week.
The primary outcome measure of the trial was negative urine tests for cocaine for the last three weeks of the nine-week trial.
A total of 18 subjects fulfilled the criteria for the primary outcome measure. Of these, 14 (28%) were treated with vigabatrin versus four (7.6%) who were treated with placebo. A logistic regression utilizing years of cocaine use and average amount per day at baseline yielded statistically significant treatment differences. The p-value was 0.009.
There were no serious adverse events reported in this trial.
"These positive results demonstrate that there is hope for the millions of individuals who suffer from the life threatening consequences of this terrible illness," said Dr. Brodie. "It also demonstrates how a dedicated team of basic scientists and clinicians who persevere in a mission can produce important medical advances by taking an idea from the bench to the community."
ABOUT OTCPICKS.COM
OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover’s Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.
Disclaimer:
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.
Release of Liability:
Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has received Internet data services from QuoteMedia (QMCI) in return for coverage on our site. For a complete list of disclosures go to http://www.otcpicks.com/disclosure_details.php. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor’s sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.
The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.
Third Party Web Sites and Information:
OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.
